GPT and metabolic dysfunction-associated steatotic liver disease: The proportion of NAFLD patients whose ALT levels returned to normal after 28 days of treatment were 0% (0/9), 0% (0/9), 22.22% (2/9), and 44.44% (4/9) in the placebo, ZSP1601 50 mg QD, 50 mg BID, and 100 mg BID groups, respectively.